title: Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours.
abstract: Combination strategies surely play a crucial role in treatment of cancer. Stereotactic ablative radiotherapy (SABR) has been described to induce abscopal effects particularly in renal cell cancer metastases. This effect is a reaction induced following irradiation of tumour tissue and occurring in another metastatic location outside the treatment field. However, this effect is limited and occurs sparsely in about 1-5% of patient. We are planning to improve the clinical outcome of this treatment in metastatic solid tumours by combining SABR with sequential immunotherapeutic treatments including vaccination strategies, adoptive cell therapy, cytokine therapy, or anti-CTLA-4 therapy.
authors.affiliation: Dept of Oncology-Pathology and KcRN, Karolinska Institutet/Karolinska University Hospital, 171 76, Stockholm, Sweden. Giuseppe.Masucci@ki.se
authors.forename: Giuseppe V
authors.initials: GV
authors.lastname: Masucci
authors.forename: Peter
authors.initials: P
authors.lastname: Wersäll
authors.forename: Rolf
authors.initials: R
authors.lastname: Kiessling
authors.forename: Andreas
authors.initials: A
authors.lastname: Lundqvist
authors.forename: Rolf
authors.initials: R
authors.lastname: Lewensohn
mesh_terms: D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D011878:Radiotherapy / Q000379:methods*